Skip to main content

Charles A. Dinarello, MD

Distinguished Professir at OLATEC Therapeutics LLC

Location: Denver, CO United States

Charles Dinarello began his career in 1971 with the objective to purify the endogenous fever-producing protein then called “leukocytic pyrogen.” Six years later, he published the isolation of a single human protein that produced fever in rabbits, now termed interleukin-1 beta (IL-1β). When injected into humans, IL-1β was highly inflammatory and produced fever and a rise in neutrophils. In 1981, he described the existence of a naturally occurring inhibitor of IL-1 activity, now known as the IL-1 receptor antagonist (IL-1Ra). In 1999, he discovered the IL-18 binding protein (IL-18BP). In 2010, his group elucidated the function of the elusive member of the IL-1 family, IL-37. Prof. Dinarello’s career continues to focus on the role of inflammatory cytokines as mediators of acute and chronic diseases. His goal is to understand the role of IL-1 and other members of the IL-1 family to provide improved and more specific treatments.

Associated Grants

  • Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.